pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·5h ago·1 min read
save

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

Sep 4, 2026·read at Fierce Biotech ↗

After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just days before Thanksgiving, showed her frontal lobe was now awash in white splotches. A genetic test the week before Christmas gave a troubling diagnosis: Alexander disease.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5h agoMenarini signs $771M deal to take Gan & Lee GLP-1 to European marketFierce Biotech
  • 1d agoChutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readoutFierce Biotech
  • 1d agoPsilocybin proves promising in neuropathic pain mouse studyFierce Biotech
  • 1d agoPfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ dealFierce Biotech
  • 1d agoAbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialFierce Biotech